Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Sacubitril/Valsartan and Ivabradine in Heart Failure
Key result
Sacubitril/valsartan and ivabradine utilization among Medicare beneficiaries increased by 156% and 46%, respectively, between 2016 and 2017, with corresponding spending increases of 241% and 59%.
Why the study?
Sacubitril/valsartan and ivabradine were approved in 2015 for heart failure with reduced ejection fraction, but few national data were available examining their contemporary use and associated costs.
Population
Medicare Part D and Medicaid beneficiaries prescribed sacubitril/valsartan or ivabradine
Comparison
Use and spending patterns between 2016 and 2017
Design
US nationwide claims-based study
Authors
Discussion
Loading...
Member takes
Implication
Rapid uptake raises Medicare spending; leaves open questions on value and appropriate use in routine practice.
Study Design
Type
Observational
Multicenter
Yes
Structured PICO
P
Population
Medicare Part D and Medicaid beneficiaries in the United States prescribed sacubitril/valsartan or ivabradine between 2016 and 2017
I
Intervention
Sacubitril/valsartan and ivabradine
O
Outcome
Changes in total spending, per-beneficiary/claim spending, number of beneficiaries, and number of claims between 2016 and 2017
Utilization and spending for sacubitril/valsartan and ivabradine increased significantly among Medicare and Medicaid beneficiaries from 2016 to 2017, though per-beneficiary spending remains below reported cost-effective thresholds.
Cite This Study
Sumarsono et al. (2019) conducted an observational in Heart failure with reduced ejection fraction. Sacubitril/valsartan and ivabradine was evaluated on Changes in total spending, per-beneficiary/claim spending, number of beneficiaries, and number of claims between 2016 and 2017. Sacubitril/valsartan and ivabradine utilization among Medicare beneficiaries increased by 156% and 46%, respectively, between 2016 and 2017, with corresponding spending increases of 241% and 59%.